Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

IXAKA LIMITED

Home Clinical Trial Sponsors and OrganizationsIXAKA LIMITED

IXAKA LIMITED

MAZARS LLP, Bristol, United Kingdom

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

4

3 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

3

75.0%

Phase 3

1

25.0%

Trial Status Distribution

Active, not recruiting

3

75.0%

Completed

1

25.0%

Clinical Trials

Trials sponsored by this organization (4)

A clinical trial to test the efficacy and safety of intra-arterial administration of REX-001 to treat ischemic ulcers in subjects with chronical limb threatening ischaemia Rutherford Category 5 and diabetes mellitus.

Active, not recruiting

Feb 202060 participants

A clinical trial to test the efficacy and safety of intra-arterial administration of REX-001 to treat ischemic ulcers in subjects with chronic limb threatening ischaemia Rutherford Category 5 and diabetes mellitus.

Active, not recruiting

Feb 202060 participants

A clinical trial to test the efficacy and safety of intra-arterial administration of REX-001 to treat ischemic ulcers in subjects with chronic limb threatening ischaemia Rutherford Category 5 and diabetes mellitus.

Active, not recruiting

Apr 201760 participants

The Efficacy and Safety of Intra-Arterial Administration of REX-001 to Treat Ischemic Ulcers in Subjects with Chronic Limb Threatening Ischaemia Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placebo-Controlled, Double-Blind, Parallel-Group, Adaptive Trial

Approvals

No approval data available

News

Adaptimmune Undergoes Major Leadership Restructuring Following Nasdaq Delisting and Asset Divestiture

- Christopher Hill has been appointed as both CEO and CFO of Adaptimmune, succeeding Adrian Rawcliffe who departed as part of the company's restructuring efforts. - The company's board has been significantly reduced to three members following the resignation of six directors, with Lawrence Alleva taking over as Chairman from David Mott. - Adaptimmune voluntarily delisted from Nasdaq in October 2025 and is now trading on the OTC Pink market, with deregistration expected to become effective around January 26, 2026. - The restructuring follows the July 2025 divestiture of TECELRA and other key cell therapy assets to US WorldMeds, leaving Adaptimmune to focus on maximizing value from remaining PRAME and CD70-targeted programs.

On this page

Overview
Clinical Trials4
Approvals
News1

Back to Organizations